Want to see CVKD full AI Analyst Report?
CVKD Stock Chart & Stats
$5.22
-$1.27(-7.12%)
At close: 4:00 PM EST
$5.22
-$1.27(-7.12%)
Day’s Range― - ―
52-Week Range$2.29 - $14.64
Previous CloseN/A
Volume16.20K
Average Volume (3M)57.36K
Market Cap
$6.94M
Enterprise Value$6.58M
Total Cash (Recent Filing)$2.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 06, 2026EPS Estimate
-1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.63
Shares Outstanding2,868,247
10 Day Avg. Volume57,981
30 Day Avg. Volume57,363
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.94
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.89K
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$29.00Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtZero reported debt gives Cadrenal structural financial flexibility through clinical development. For a pre-revenue biotech, low leverage reduces default risk and preserves the ability to prioritize R&D or negotiate partner deals without debt servicing constraints, improving long-term optionality.
FDA-Guided Phase 3 Path For CAD-1005Receiving explicit FDA guidance on pivotal trial design materially reduces regulatory uncertainty and clarifies endpoints, size and safety requirements. That durable reduction in development and regulatory risk supports a clearer path to a potential 2029 U.S. filing and enhances partnering or licensing prospects.
Orphan / Dual-Track Commercial StrategyA dual-track strategy plus pursuit of Rare Pediatric Disease Designation targets orphan incentives and efficient trials. Focusing tecarfarin on Kawasaki disease and regional markets can yield faster, lower-cost development and partner interest, strengthening long-term commercialization options.
Bears Say
Pre-Revenue With Rising Cash BurnSustained, accelerating cash burn without product revenue creates a persistent funding requirement. Over multiple quarters this weakens financial resilience and increases the probability of dilutive financings, constraining long-term R&D pacing and strategic independence unless partnered or financed.
Eroding Equity CushionRapid erosion of shareholders' equity reduces the company's balance-sheet buffer to withstand development setbacks. With limited internal capital, Cadrenal remains structurally dependent on external financing, raising dilution risk and limiting capacity to absorb trial delays or expand programs without partners.
Executive Turnover In Key RolesLosing a CMO amid pivotal program transitions and recent CFO changes concentrates execution risk. Disruptions in clinical leadership and finance can slow protocol execution, regulatory interactions and partner negotiations, increasing program delivery risk during critical trial and filing planning stages.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $2.29 and its highest was $14.64 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $6.94M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 22 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.55.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 2,868,247 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.431%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$29.00
▲(455.56% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
10.41% Insiders
2.05% Mutual Funds
0.03% Other Institutional Investors
85.72% Public Companies and
Individual Investors